Market Overview
Global Buprenorphine Hydrochloride market was valued at USD 131 million in 2024. The market is projected to grow from USD 134 million in 2025 to USD 151 million by 2031, exhibiting a CAGR of 2.1% during the forecast period.
USD 151 million by 2031 USD 131 million in 2024
of 2.1%
Tablets Injection
Tablets represent the dominant formulation due to widespread adoption in outpatient settings for managing opioid dependence and chronic pain, offering superior stability, ease of administration, and patient compliance compared to injectable forms, which are generally reserved for acute hospital-based pain management due to their faster onset of action and requirement for professional administration.
By Application
Analgesic
Opioid Antagonist
Others
Analgesic is the leading application segment, as buprenorphine hydrochloride's unique pharmacology as a partial mu-opioid receptor agonist provides effective relief for moderate to severe chronic pain with a favorable safety profile characterized by a ceiling effect on respiratory depression, making it a preferred choice for long-term pain management in an evolving regulatory landscape focused on reducing opioid misuse.
Our Key Players
Resonance Laboratories
Siegfried Sanofi
Johnson Matthey
Mallinckrodt
Noramco
Unichem Laboratories
Arevipharma
https://www.24lifesciences.com
